SRR2780123
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- E2F_TARGETS+0.400
- DNA_REPAIR+0.300
- MYC_TARGETS_V1+0.300
- G2M_CHECKPOINT+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- BILE_ACID_METABOLISM+0.100
- FATTY_ACID_METABOLISM+0.100
- PANCREAS_BETA_CELLS+0.100
- PEROXISOME+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.600
- IL6_JAK_STAT3_SIGNALING-0.600
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- COMPLEMENT-0.500
- INFLAMMATORY_RESPONSE-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- IL2_STAT5_SIGNALING-0.400
- KRAS_SIGNALING_UP-0.400
- TGF_BETA_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG392 | — | — | 0.928 |
| 2 | SAMN03290891 | — | — | 0.912 |
| 3 | TCGA-77-8154-01A-11R-2247-07 | — | cohortSQ1 | 0.910 |
| 4 | 20110070.TNBC | — | E | 0.908 |
| 5 | TCGA-85-8352-01A-31R-2326-07 | — | cohortMD1 | 0.907 |
| 6 | 20120209.TNBC | — | E | 0.904 |
| 7 | TCGA-UY-A78N-01A-12R-A33J-07 | — | — | 0.904 |
| 8 | TCGA-NC-A5HH-01A-11R-A26W-07 | — | cohortMD1 | 0.900 |
| 9 | SRR5088895 | — | — | 0.899 |
| 10 | EPT0810 | EPN | Posterior Fossa EPN | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |